Table 2 AMPs as therapeutic agents

Iseganan

III

Oral mucositis in patients receiving radiotherapy for head and neck malignancy

Ptotegrin-1 (pigs)

Oral solution

[71, 72]

TD-1792

III

Gram positive infections/ skin and soft tissue infections

Synthetic peptide

Topical

[73]

CZEN-002

IIb

Vaginal candidiasis

αMSH (human)

Vaginal gel

[73]

NP-432

Pre-clinical

Methicillin-resistant Staphylococcus aureus (MRSA) / P. aeruginosa C. difficile infections

Synthetic peptide

Intravenous

[73]

lytixar

I/II

Uncomplicated gram-positive skin infections, impetigo, nasal colonization with S. aureus

Synthetic antimicrobial peptidomimetics

Topical hydrogel

[74]

C16G2

II

Dental caries

synthetic

Topical

[73]

Omiganan

II/III

Catheter infection and rosacea

Indolicidine (bovine)

Topical gel

[75]

TD-6424

III

Osteomyelitis Bacterial infection

Synthetic peptide

Intravenous

[73]

PXL01

II

Prevention of post-surgical adhesion formation in hand surgery

Lactoferricin (human)

Hyaluronic acid based- hydrogel for administration at the surgical site

[2]

hLF1-11

I/II

Bacteremia and mycosis in immunocompromized haematopoetic stem cell transplant recipients

Lactoferricin (human)

Intravenous treatment

[75]

Novexatin

II

Onychomycosis

Defensins (human

Topical brush-on treatment

[75]

LL-37

I/II

Hard-to-heal venous leg ulcers

LL-37 (human)

Solution for administration in the wound bed

[75]

PAC-113

II

Oral candidiasis in HIV seropositive patients

Histatin3 (human saliva)

Mouth rinse

[75]